期刊文献+

p53、CK20表达与膀胱尿路上皮癌分级的关系 被引量:3

Relationship Between Expressions of p53 or CK20 and Pathological Grade of Uroepithelium Carcinoma of Bladder
暂未订购
导出
摘要 目的探讨p53、CK20在膀胱尿路上皮癌(BUC)组织中的阳性表达与肿瘤分级的关系。方法采用免疫组化法分别检测118例BUC、21例良性病变组织中p53、CK20的表达,并分析两者与BUC病理分级的关系。结果 BUC组织中的p53阳性率为88.1%,明显高于良性病变组织的61.9%,在高级别BUC组织中的阳性表达率(+++)明显高于低级别BUC(P<0.05);CK20在BUC组织中的阳性表达率为28.8%,明显高于良性病变组织的0.0%,在高级别BUC组织中的阳性表达率(++^+++)明显高于低级别BUC。结论p53、CK20在BUC组织中呈阳性表达,且BUC的分级越高,阳性表达越强。 Objective To investigate the relationship between expressions of p53 or CK20 and pathological grade of uroepithelium carcinoma of bladder (BUC). Methods The expression levels of p53 and CK20 in the 118 cases of BUC and the 21 cases of benign lesions were detected with immunohistochemical method, and the relationship between expressions of p53 or CK20 and pathological grade of BUC were analyzed. Results The expression rate of p53 in the BUC was higher than that of the benign lesion ( 88. 1% vs 61.9% , P 〈 0. 05 ), the expression rate ( +++ ) of the high grade BUC was higher than that of the low grade BUC ( P 〈 0. 05 ). The expression rate of CK20 in the BUC was higher than that of the benign lesion (28.8% vs 0.0% ,P 〈0.05) ,the expression rate ( ++ or +++ ) of the high grade BUC was higher than that of the low grade BUC (P 〈 0.05). Conclusion The positive expressions of p53 and CK20 was observed in the BUC tissues ,and their positive expressions are correlated with higher tumor grade of BUC.
出处 《肿瘤基础与临床》 2013年第6期461-464,共4页 journal of basic and clinical oncology
关键词 膀胱肿瘤 病理分级 P53 CK20 bladdler neoplasmas pathological grade p53 CK20
  • 相关文献

参考文献4

二级参考文献51

共引文献16

同被引文献25

  • 1余东海,周四维,章慧平,叶章群.CK20及Cjun在膀胱肿瘤的表达和临床意义[J].临床泌尿外科杂志,2005,20(5):288-290. 被引量:11
  • 2侯燕,胡群,刘爱国,张柳清,蒋艳,陶红芳,胡迎.Survivin在儿童急性白血病中的表达和P53的相关性及其临床意义[J].中国实用儿科杂志,2005,20(5):283-285. 被引量:6
  • 3李彬,徐涛,赵晖,王月清.P27^(kipl)、CyclinD_1在膀胱癌中的表达及其意义[J].实用医学杂志,2006,22(22):2607-2610. 被引量:2
  • 4Nadal A,Cardesa A. Molecular biology of laryngeal squamous cell carcinoma[ J ]. Virchows Arch ,2003,442 ( 1 ) : 1 - 7.
  • 5Ohtani N, Yamakoshi K, Takahashi A, et al. The pl61NK4a - RB pathway: molecular link between cellular senescence and tumor suppression [ J ]. Med Invest ,2004,51 ( 3/4 ) : 146 - 153.
  • 6Takeba Y, Kumai T, Matsumoto N, et al. Irinotecan activates P53 with its active metabolite,resuhing in human hepatocellular carci- noma apoptosis [ J ]. J Pharmacol Sci,2007,104 ( 3 ) : 232 - 242.
  • 7Bau DT,Tsai MH,Lo YL,et al. Association of P53 and p21 ( CD- KNIAZWAFI/C1PI) polymorphisms with oral cancer in Taiwan patients [ J ]. A nticancer Res, 2007,27 ( 3 B ) : 1559 - 1564.
  • 8Jung .IT, Kim DH, Kwak EK, et al. Clinical role of Bcl - 2, Bax, or P53 overexpression in Periph - eral T - cell lymphomas [ J ]. Ann Hematol, 2006,85 ( 9 ) :575 - 579.
  • 9Farazi PA,Glickman J, Homer J,et al. Cooperative interactitms of P53 mutation, telomere dysfunction, and chronic liver damage in hepatocellular carcinoma progression [ J ]. Cancer Res, 2006,66 ( 9 ) :4766 - 4773.
  • 10Moll R,Schiller DL, Franke WW. Identification of protein IT of the intestinal cytoskeleton as a novel type I cytokeratin with un2 usual properties and expression patterns [ J ]. Cell Biol, 1990,111 ( 2 ) : 567 - 580.

引证文献3

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部